Eyes and vision
What human research has studied for macular degeneration and other eye outcomes, across every ingredient in this guide, strongest evidence first. A grade describes the evidence, not a recommendation.
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. Ask a doctor or pharmacist before use, especially with medicines, in pregnancy or for a child.
How strong the evidence is
Where eyes and vision sits on the supplement body map; colored by its strongest grade here.
Findings by ingredient
| Ingredient | Grade | What was studied and found |
|---|---|---|
| Lutein and zeaxanthin | B | Macular pigment optical density and visual acuity in people with or at risk of AMD. A meta-analysis of five RCTs (445 participants) found lutein raised macular pigment optical density and gave a milder improvement in visual acuity versus placebo; the authors said the number of studies was not adequate for conclusive evidence. sources |
| Manuka honey | B | Dry eye (honey applied to the eye). A meta-analysis of 5 RCTs (288 adults) reported improved symptom scores, tear evaporation and ocular surface staining versus control; the authors state study limitations affect reliability and call for high-quality trials. sources |
| Multivitamin/mineral supplements | B | Progression of age-related macular degeneration (AREDS formula). AREDS (4,757 participants enrolled, mean 6.3 years; high-dose vitamins C and E, beta-carotene, zinc, copper) lowered the odds of advanced AMD by about 28% (about 25% lower estimated 5-year risk) in people at high risk; it did not affect AMD onset. sources |
| Zinc | B | Advanced age-related macular degeneration. AREDS (4,757 adults aged 55–80; about 5 years): in those at high risk of advanced AMD, 80 mg zinc (as zinc oxide) plus antioxidants and 2 mg copper gave about 25% lower risk than placebo; AREDS2 results with 25 mg were called preliminary. sources |
| Bilberry | C | Eye fatigue from screen work. RCT in office workers (88 enrolled, 80 completed): 480 mg/day extract for 8 weeks lessened the screen-induced drop in flicker fusion and some fatigue symptoms versus placebo; near-point accommodation did not change. sources |
| Butcher's broom | C | Diabetic retinopathy. One 3-month randomized study (60 patients) compared Ruscus extract with troxerutin and buckwheat herb; changes in retinal electrical activity were not statistically significant versus baseline. sources |
| Dunaliella | C | Retinal function in retinitis pigmentosa. In a crossover RCT (29 analyzed), 300 mg/day D. bardawil powder (about 20 mg beta-carotene) for 90 days raised dark-adapted ERG b-wave amplitude versus placebo; visual field and acuity did not change. sources |
| Goji | C | Macular pigment in healthy middle-aged adults. In an unmasked 90-day trial in 27 adults aged 45-65, 28 g goji berries five times weekly increased macular pigment optical density; a lutein/zeaxanthin supplement group showed no change. sources |
| Goji | C | Retinitis pigmentosa. A 12-month double-masked placebo-controlled trial (42 completers) found visual acuity better preserved with a Lycium barbarum supplement; visual field and electroretinogram measures did not differ. sources |
| Lutein and zeaxanthin | C | Lutein/zeaxanthin in place of beta-carotene in the AREDS formulation. In 10-year AREDS2 follow-up (3,882 participants), an epidemiologic study, lutein/zeaxanthin versus beta carotene had HR 0.85 for late AMD; beta carotene had been replaced by lutein/zeaxanthin in the revised supplement. sources |
| Lutein and zeaxanthin | C | Retinopathy of prematurity in preterm infants. Three RCTs (406 preterm infants) of oral lutein/zeaxanthin versus placebo failed to show any reduction in retinopathy of prematurity, bronchopulmonary dysplasia, sepsis, NEC or mortality. sources |
| Palmitoylethanolamide (PEA) | C | Intraocular pressure in glaucoma or ocular hypertension. A systematic review included 6 studies (199 patients) and pooled 3; PEA reduced intraocular pressure. sources |
| Sea buckthorn | C | Dry eye symptoms. In an RCT (100 adults, 86 completed), 2 g/day sea buckthorn oil for 3 months limited the cold-season rise in tear osmolarity versus placebo and lowered some symptom intensities. sources |
| Tea tree oil | C | Demodex eyelid mites (eyelid inflammation). Several studies have looked at this use, but effectiveness is uncertain. sources |
| Vitamin A | C | Advanced age-related macular degeneration (AMD). AREDS (formula with 15 mg beta-carotene, vitamins C and E, zinc, copper; 5 years) reported 25% lower risk of advanced AMD; AREDS2 (4,203 people) found beta-carotene was not a required ingredient. sources |
| Vitamin C | C | Age-related macular degeneration (AMD). In AREDS (3,597 people, 500 mg with other antioxidants, 6.3 years) high-risk participants had 28% lower risk of advanced AMD, but evidence does not show vitamin C alone affects AMD risk. sources |
| Vitamin E | C | Age-related macular degeneration (AMD). AREDS (formula with 400 IU vitamin E plus other nutrients) reported 25% lower risk of advanced AMD at 5 years in high-risk people; two trials of vitamin E alone or with beta-carotene found no protection. sources |
| Bilberry | X | Night vision in healthy people. A systematic review of 12 placebo-controlled trials found the 4 most recent RCTs negative; negative results came from more rigorous trials. Improvement of normal night vision is not supported by rigorous studies. sources |
| Lutein and zeaxanthin | X | Progression to advanced age-related macular degeneration (AMD), added to the AREDS formulation. AREDS2 (4,203 people aged 50–85 at risk of advanced AMD; median 5 years): adding lutein 10 mg + zeaxanthin 2 mg to the AREDS formulation did not further reduce risk of progression to advanced AMD in primary analyses (HR 0.90). sources |
| Lutein and zeaxanthin | X | Cataract surgery and vision loss. In AREDS2 (3,159 participants with a natural lens, median 4.7 years), lutein/zeaxanthin had no statistically significant overall effect on cataract surgery (HR 0.96) or vision loss. sources |
| Omega-3 fatty acids | X | Progression of age-related macular degeneration. AREDS2, with more than 4,000 participants, found that adding EPA and DHA to the AREDS supplement formula provided no additional benefit. sources |
| Vitamin C | X | Cataracts. AREDS participants did not have a significantly lower risk of developing cataracts or cataract progression; a Swedish cohort linked about 1,000 mg/day supplements to 25% higher cataract extraction risk. sources |
| Vitamin E | X | Cataracts. AREDS found no apparent effect on cataract development or progression over about 6.3 years, and AREDS2 confirmed this. sources |
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.